JZP 110

Drug Profile

JZP 110

Alternative Names: ADX-N05; ARL-N05; JZP-110; SKL-N05

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator SK Holdings
  • Developer Jazz Pharmaceuticals plc; SK biopharmaceuticals
  • Class Sleep disorder therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Neurotransmitter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Narcolepsy; Sleep apnoea syndrome
  • Phase II Hypersomnia
  • No development reported Depressive disorders

Most Recent Events

  • 01 Jan 2017 Phase-II clinical trials in Hypersomnia (in patients with Parkinson's disease) in USA (PO) (NCT03037203)
  • 28 Nov 2016 Jazz Pharmaceuticals completes enrolment in a phase III trial for Narcolepsy in USA, Canada, Finland and Germany
  • 26 Sep 2016 Jazz Pharmaceuticals completes enrolment in a phase III trial in Sleep apnoea syndrome in USA, Netherlands, France, Germany and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top